Radiopharm Reports FDA Clearance To Initiate First-in-human Phase 1 Trial Of RV-01

(RTTNews) - Radiopharm Theranostics (RADX) announced that the FDA has provided clearance of the company's Investigational New Drug application for Betabart or RV-01, its Lu177-B7H3 monoclonal antibody. RV-01 is the first radiopharmaceutical therapeutic agent developed by Radiopharm Ventures, the Joint Venture formed between Radiopharm Theranostics and MD Anderson Cancer Center.

"FDA clearance to initiate our first-in-human Phase 1 clinical trial of RV-01 represents a major milestone for Radiopharm Theranostics and our joint venture with MD Anderson Cancer Center," said Riccardo Canevari, CEO and Managing Director.

For More Such Health News, visit rttnews.com.